SmartTRAK takes a quick look at recent trends that may influence the Total Joints Market in the near and long term

Wall Street Analysts recently called out two trends specifically that could influence the Total Joints Market. One trend, the strengthening of the US dollar, is likely to impact the global market in 2024. Another trend is the increased prescribing of GLP-1 drugs, such as Ozempic, Wegovy, Byetta and Mounjaro, medications first used to treat Type 2 diabetes, as a treatment for obesity. This has the potential to impact the market down the road. In this downloadable article, SmartTRAK maps out the potential impact of these trends.

To download and read the complete article by SmartTRAK's Lisa Mahan, Product Development & IT, Sr. Analyst TJ&E, just click the button below.

Medtronic Neurovascular President Dan Volz discusses expanding patient access to neurovascular therapies through innovation and globalization in an interview with SmartTRAK.

Medtronic Neurovascular President Dan Volz discusses innovation, globalization and the Company’s plans to double the number of neurovascular patients treated annually in three years in an interview with SmartTRAK. Volz said the Company is driving growth in Neurovascular through innovative business models and strategic investments in remote connectivity and the Medtronic Neurovascular Co-Lab Platform, a novel incubator designed to accelerate innovation in stroke care and treatment. To find out more about the Company and its latest innovations, click on the video to listen to the full interview (27:30 min). To download a transcript of the complete interview, just click the button below.

Anne Staylor here with SmartTRAK. Today I have the pleasure of interviewing Dan Volz, president of Medtronic Neurovascular. Dan, thank you for speaking with me today.

Dan Volz: It's my pleasure. It's good to talk to you.

I haven't talked to you for a while and I was hoping to catch up with you at SNIS when it was here in San Diego. Now that we are talking, let's just start broadly and talk from your perspective, what's important for us to know about Medtronic Neurovascular and what are your top priorities for fiscal year 2024?

DV: It's good to see you and I'm sorry that I missed you down in San Diego. That was a pretty quick up and back for me, but for us obviously it's about the patients and we had a pretty important milestone in 2022. In a 12-month period we helped treat 250,000 people, so that was a great celebration for us as a business. But I think even more importantly, it kicked off our strategic planning process to double that number in three years. And so everything that we do is centered on how do we drive toward that number? And there's a lot that goes into that, but it starts with obviously innovation and how are we innovating in our portfolio? What are we doing organically and what are we looking at inorganically to drive toward that number? And you know these statistics as well as anyone, there's 15 million strokes and we only treat five to 600,000 of them a year ...

To download and read the transcript of the complete interview with Dan Volz, president of Medtronic Neurovascular, by SmartTRAK's Anne Staylor, Executive Editor, VP & GM of Neuro Therapies, just clickthe button below.

Fertram Sigurjonsson, CEO of Kerecis, discusses the recent acquisition, how the Company has evolved over the last decade and key milestones along its “Road to Success” in an interview with SmartTRAK.

Increasing acceptance of diagnostics, as well as the repositioning of existing technologies, could help drive growth in European wound care.

Pressure injuries are globally accepted as a major healthcare challenge. SmartTRAK estimates there were 10.2MM pressure ulcers in Europe in 2022, with 4.0MM being stage III or IV. At the 23rd European Pressure Ulcer Advisory Panel (EPUAP) meeting recently held in Leeds, UK, the main focus of the meeting was on diagnosing and treating the more challenging stage III/IV pressure ulcers. In this downloadable article SmartTRAK explores how diagnostics continues to be a major driver of innovation within the space and how companies and products previously focused on treatment are now firmly positioning themselves within the prevention space, where SmartTRAK will soon offer brand-new insights.

Among the many topics covered in the article are:

• Diagnostics
  The perception of diagnostic tools within European wound care appears to be evolving. Previously, they had been viewed as aspirational but unaffordable luxuries, but are now becoming ...
  
  
• Wound Treatments
  There was a distinct lack of new technologies for the treatment of pressure injuries on display in the exhibition, with existing dressings and negative pressure wound therapy (NPWT) being the main solutions on stands. New treatment solutions were ...
  
  
• Dressings for Pressure Injury Prevention
  Historically, clinicians have used dressings designed for managing open wounds as a method of pressure injury prevention. In the last decade, more and more dressings companies have been recognizing the possibilities offered within this market. Published evidence suggests ...
  
  To download and read the complete "Prevention Proves Better than Cure for European Dressing Companies" perspective article by SmartTRAK's  Aniko Szeker, Sr Analyst, Wound and Kris Finn, Sr Analyst, Wound, please click the button below.

Csaba Dózsa, habil PhD MSc, Health Economist, discusses his model for cost-effectiveness in the prevention and treatment of pressure injuries in an interview with SmartTRAK.

In this interview, Prof. Dózsa unveils his groundbreaking pressure injury (PI) prevention costing model. With a 20-year background in health economics, he embarked on this journey from Hungary's National Health Insurance Fund. His expertise shaped the German DRG point system locally and steered home care development. Establishing Med-Econ Ltd., he delved into diverse health economic studies, culminating in a sophisticated, non-linear model for PI prevention costs.

The model's complexity stems from recognizing intricate healthcare inputs and outcomes. It calculates annual PI costs across scenarios: implementing preventive care bundles with or without multi-layer dressings, and treatment-only approaches. Designed as a calculation framework, it showcases the efficacy of preventive wound care.

Among the many questions answered by Prof, Dózsa in this interview are:

• Can this model be used in any health and political environment?
• How does the use of this model affect a hospital's use of dressings?
• How would you describe the cost structure of prevention and treatment?
• Can this model and its outcome lead to systemic changes?
• How long would it take a hospital or hospital system to adapt the model to their data?
• Can this model be used equally in the case of higher-risk patients, older patients or in hospitals that see proportionally more of these patients?

The interview, conducted by Anikó Szekér, SmartTRAK Senior Analyst, Wound Care, offers insights into Prof. Dózsa's journey and his PI prevention costing model's potential. To download a complete transcript of the interview, just click the button below.

SmartTRAK was on-site at ASPN 2023 covering industry-sponsored RCT updates and data reveals, as well as new players and trends in the interventional pain space.

As the number of patients suffering from chronic pain increases, the interventional pain market continues to grow. Physicians and device developers are rising to the challenge by offering more personalized pain treatment options for an expanding list of indications. As a result, new differentiators for spinal cord stimulation (SCS) players have emerged, as well as newcomers in the peripheral nerve stimulation (PNS) market. Beyond neuromodulation, minimally-invasive surgical (MIS) spine procedures, sacroiliac (SI) joint fusion and regenerative medicine products also provide innovative solutions for chronic pain management. In this interesting article, SmartTRAK highlights the newest data, innovation and market developments at the American Society of Pain and Neuroscience (ASPN) 2023 Annual Meeting held in Miami, FL.

Among the many topics discussed in comprehensive detail in this article, which can be downloaded here, are:

• SCS Sees Cutthroat Competition
  • MRI Compatibility and Closed-Loop SCS
  • Painful Diabetic Neuropathy (PDN)
  • Artificial Intelligence, Programming Solutions and Remote Monitoring
• Expanding Horizons in PNS
  • Types of Peripheral Nerve Stimulation
  • Outcomes, Comfort and Wearability for Externally-powered Devices
  • Injectrode Technology
• What’s New in MIS Spine and SI Joint Fusion
  • Leveraging Enabling Technology for Pain Procedures
  • Innovations in MIS Spine and SI Joint Instrumentation
• Scientific Focus on Biologics and Regenerative Medicine

To identify current and future trends in interventional pain management and PNS, SmartTRAK recently surveyed 30 interventional pain physicians, including 18 who perform PNS, to get an inside view of procedure trends, what treatments and devices they use and who they see as future winners in the chronic pain space. To purchase the results of this comprehensive survey, see SmartTRAK’s Trends in Interventional Pain Management and PNS.

To download a complimentary copy of the complete "ASPN 2023: Advancements in Interventional Pain Treatment" article, just click the button below.

At the 2023 Annual Meeting in monumental Washington DC, the Biologic Association and the American Society of Orthopaedic Surgeons (AAOS) teamed up with American Orthopaedic Society for Sports Medicine (AOSSM) to spotlight the growing interest in and latest advancements of biologics in musculoskeletal medicine. Taking center stage and garnering attention was the idea of “biological healing” and the use of biologics in various conditions and at different points of a continuum of care.

Not surprisingly, the Biological Association focused more on autologous therapies, cell culturing and the next generation of biologics, while the AOSSM meeting explored the current use and growing trends of traditional orthobiologics in orthopedic applications. This article, which is downloadable here, is part one in a two-part series highlighting key takeaways from the Biologic Association meeting, including:

• Biologic Association Key Takeaways
• Rules of Engagement: Regulations and Needed Standards
  • “Same Surgical Procedure Exception” Guidance
  •  Standards for Autologous Orthobiologics
  • Driving Better Patient Outcomes
• Current Use of Autologous Therapies and Next Generation of Biologics
  • Current Practice
  • Next Generation of Biologics
• Notable Investigative Technologies

Although several biologics seem promising to treat musculoskeletal conditions, there is still an uphill battle for widespread use. Current challenges include ...

To download "Biologics in Musculoskeletal Medicine," Part One of the series of articles by Kimberly French, SmartTRAK's GM, Orthobiologics and Regenerative Medicine, just click the button below. Look for Part Two in this series, which will cover key takeaways from AOSSM, highlighting the current use of Orthobiologics and growing trends, in the coming weeks.